In this report, we cover catalysts from 32 drugs, devices, diagnostics, and deals expected to occur in the fourth quarter of 2023. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

These data points were provided using a combination of Pharmapremia, our drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker. At the end of this report, we have included a list of Large Impact catalysts through the fourth quarter of 2023.